NCT05866952 Ventilatory and Perfusion Abnormalities in Individuals With Post-Acute Sequelae of SARS-CoV-2 Infection
| NCT ID | NCT05866952 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tufts Medical Center |
| Condition | Post-Acute COVID-19 |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2023-06-05 |
| Primary Completion | 2026-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 40 participants in total. It began in 2023-06-05 with a primary completion date of 2026-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Prospective cohort study to evaluate the utility of quantitative CT analysis to assess ventilation and perfusion defects in patients with Post-acute Sequelae of SARS-CoV-2 (PASC) and functional limitations
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 * Self-reported or documented SARS-CoV-2 infection by RT-PCR or Antigen testing \> 3 months ago or no previous history of SARS-CoV-2 infection (control group only) * Normal or mild abnormalities on baseline Pulmonary Function Tests (PFTs) * New or worsening symptoms of chronic fatigue, dyspnea or exercise intolerance after COVID-19 with otherwise unclear etiology (PASC group only) Exclusion Criteria: * SARS-CoV-2 infection by RT-PCR or Antigen testing within the last 3 months * Inability to provide consent or non-English speaking * Pregnancy * Any respiratory infection in last 4 weeks * PFT relative contraindications * History of major cardiovascular, pulmonary, renal, hepatic, autoimmune or neuromuscular disease including asthma, COPD, interstitial lung disease, heart failure, pulmonary arterial hypertension, or prior pulmonary embolism * Active malignancy undergoing treatment or history of malignancy involving the lung
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05866952 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Post-Acute COVID-19. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05866952 currently recruiting?
Yes, NCT05866952 is actively recruiting participants. Contact the research team at tuftsmccorstudy@tuftsmedicalcenter.org for enrollment information.
Where is the NCT05866952 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT05866952 clinical trial?
NCT05866952 is sponsored by Tufts Medical Center. The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.